Evolus, Inc.(EOLS)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Evolus, Inc. (EOLS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores EOLS at 39.0/100 on a 32-signal composite quality model, placing it at rank #2,167 of 2,962 stocks — the bottom half of the AI-ranked universe. EOLS scores in the top quartile across revenue growth (77.7). Areas of concern include balance sheet strength (13.7) and free cash flow (19.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 20.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Evolus, Inc. reports quarterly revenue of $84.1M, net income of $-8.1M, an operating margin of -5.4%. Top institutional holders of EOLS by reported 13-F value include Nantahala Capital Management, BlackRock, BRAIDWELL, based on the most recent SEC filings. EOLS trades on the Nasdaq exchange and files with the SEC under CIK 1570562. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EOLS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Evolus, Inc. directly from SEC EDGAR.